Merck & Co., Inc. recently reported robust earnings, yet the market response was lukewarm. Investors overlooked several positive aspects beneath the surface. Unusual expenses, totaling US$4.2 billion, ...

Merck's Phase 3 trial shows Keytruda plus Padcev improves survival in muscle-invasive bladder cancer patients ineligible for ...

This week, Merck filed a notice in accordance with New Jersey's WARN Act, indicating it plans to eliminate 58 positions at ...

Merck KGaA is in the investment-grade market Tuesday, a day after holding investor calls, to help fund its $3.9 billion ...

Merck in 2019 inked a deal to evaluate the combination of its blockbuster cancer drug Keytruda with Pacdev from Astellas and Seagen, which Pfizer acquired in a $43 billion deal that closed in late ...

Pfizer (PFE) stock is in focus as the company and Astellas (ALPMF) post a late-stage trial win for their cancer drug Padcev ...

Merck & Co., Inc. has kicked off two Phase 3 trials for its experimental PrEP therapy, MK-8527. **The trials, EXPrESSIVE-10 ...

IO Biotech (IOBT) stock rallies as cancer vaccine, Cylembio, with Merck's (MRK) Keytruda outperforms in a late-stage trial ...

XTRA:MRK 1 Year Share Price vs Fair Value Explore Merck KGaA's Fair Values from the Community and select yours ...

Debuting on August 9, Tori Jones Studio will present “Block Island Visions II: Monoprints, Oil Paintings, and Works on Paper, ...

The expiration of Viatris’s EpiPen patent in September 2025 will likely result in increased competition and lower costs in ...

Since its inception, Merck Foundation has provided 63 scholarships to Nigerian doctors, enabling them to specialise in 42 ...